State of the Art of Chronic Spontaneous Urticaria in Italy: a Multicentre Survey to Evaluate Physicians' and Patients' Perspectives
Overview
Authors
Affiliations
Objective: To assess the clinical status of chronic spontaneous urticaria (CSU) and understand treatment approaches in Italy through specialists who treat CSU (dermatologists and allergy specialists) and CSU patients' experience.
Design: Multicentre survey.
Setting: Online structured questionnaires (one for physicians and one for patients).
Participants: Physicians and patients with CSU in Italy.
Interventions: None.
Primary/secondary Outcomes: Physician and patient attitudes/experiences.
Results: Survey results from 160 allergy and 160 dermatology specialists show that specialists see a median of 40 (IQR 20-80) patients with CSU/year. While most specialists (56%) know the CSU guidelines, only 27% use them regularly (36% of allergy specialists vs 18% of dermatologists). This is reflected in treatment choices with differences between physicians who use guidelines regularly and those who do not: 91.6% vs 71.7% choose standard-dose, non-sedating antihistamines as first-line treatment; 85.9% vs 56.0% select up-dosing for second-line treatment and 65.3% vs 37.2% add leukotriene receptor antagonists or H-antihistamines as third-line treatment. The diaries from 1385 patients highlight that, regardless of treatment regimen, 29.4% of currently treated patients are refractory to therapy. Specialists aim to resolve symptoms and only 7.8% report improving quality of life (QoL) as a priority. Only 16.6% of specialists are familiar with and use the Urticaria Activity Score while 46.9% do not know it. Overall, 537 patients with CSU were surveyed (median age 37 years, IQR 30-46; 44.3% men; median disease duration 5 years, IQR 3-20). Approximately 62% confirm that CSU negatively impacts their QoL. Patients also complain of difficulties in getting information and support: <5% of medical centres provide patient support services.
Conclusions: In Italy, the gap between guideline-based care and QoL-related needs in CSU patients affects treatment satisfaction. This information could be used to improve the management of CSU in Italy.
Mobeen A, Ahmad A J Tradit Complement Med. 2021; 11(4):303-310.
PMID: 34195024 PMC: 8240108. DOI: 10.1016/j.jtcme.2020.12.003.
Chu C, Hammadi A, Agmon-Levin N, Atakan N, Farag A, Arnaout R World Allergy Organ J. 2020; 13(4):100117.
PMID: 32382379 PMC: 7200453. DOI: 10.1016/j.waojou.2020.100117.
Jankowska-Konsur A, Reich A, Szepietowski J Postepy Dermatol Alergol. 2019; 36(2):184-191.
PMID: 31320852 PMC: 6627267. DOI: 10.5114/ada.2019.84594.
Yang S, Lin Y, Lin J, Chen H, Hu S, Yang Y Front Pharmacol. 2019; 9:1474.
PMID: 30618764 PMC: 6305335. DOI: 10.3389/fphar.2018.01474.
Management of chronic spontaneous urticaria: a worldwide perspective.
Kolkhir P, Pogorelov D, Darlenski R, Caminati M, Tanno L, Pham D World Allergy Organ J. 2018; 11(1):14.
PMID: 29988758 PMC: 6030778. DOI: 10.1186/s40413-018-0193-4.